Literature DB >> 17900996

Transplantation trends in primary biliary cirrhosis.

Jarone Lee1, Adam Belanger, John T Doucette, Carmen Stanca, Scott Friedman, Nancy Bach.   

Abstract

BACKGROUND & AIMS: Ursodeoxycholic acid (UDCA) has shown efficacy in primary biliary cirrhosis (PBC), a chronic, slowly progressive disease. We hypothesized that UDCA use would reduce the need for liver transplantation in PBC. Our study's aim was to assess liver transplantation requirements in PBC over a 12-year period. For comparison, we studied patients with primary sclerosing cholangitis (PSC) because it shares similar characteristics to PBC, but with a decreased response to UDCA.
METHODS: PBC and PSC transplant data of first-time liver recipients from the United Network for Organ Sharing database were collected from 1995 to 2006.
RESULTS: The absolute number of liver transplantations in the United States increased an average of 249 transplants per year (P < .001). The absolute number of transplants performed for PBC decreased an average of 5.4 cases per year (P = .004). The absolute number of transplantations for PSC showed no statistical change (P = .621). The trends for the absolute number of individuals added to the transplant waitlist showed a similar pattern: (1) an increase in total listings for transplants of all diagnoses (beta = 265; P = .001); (2) a decrease in PBC (beta = -12.1; P < .001); (3) and no change for PSC (beta = -5.434; P = .083).
CONCLUSIONS: The liver transplantation burden of PBC in the United States decreased between 1995 and 2006. This is despite an increase in total liver transplants and no change in transplant rates for PSC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900996     DOI: 10.1016/j.cgh.2007.07.015

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  30 in total

Review 1.  Primary sclerosing cholangitis: is any treatment worthwhile?

Authors:  Ashley Barnabas; Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 2.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

3.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

4.  38-year-old woman with abnormal liver enzymes and hyperlipidemia.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

5.  Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.

Authors:  George Cholankeril; Humberto C Gonzalez; Sanjaya K Satapathy; Stevan A Gonzalez; Menghan Hu; Mohammad Ali Khan; Eric R Yoo; Andrew A Li; Donghee Kim; Satheesh Nair; Robert J Wong; Paul Y Kwo; Stephen A Harrison; Zobair M Younossi; Keith D Lindor; Aijaz Ahmed
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-08       Impact factor: 11.382

Review 6.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 7.  Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.

Authors:  Amitkumar Patel; Anil Seetharam
Journal:  J Clin Exp Hepatol       Date:  2016-10-21

8.  Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Authors:  Runalia Bahar; Kimberly A Wong; Chung H Liu; Christopher L Bowlus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

Review 9.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

Review 10.  The diagnosis of primary biliary cirrhosis.

Authors:  Christopher L Bowlus; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.